Personal information

Activities

Works (50 of 112)

Items per page:
Page 1 of 3

Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment

Hepatology
2025-03 | Journal article
Contributors: Ciro Celsa; Giuseppe Cabibbo; Claudia Angela Maria Fulgenzi; Salvatore Battaglia; Marco Enea; Bernhard Scheiner; Antonio D’Alessio; Giulia F. Manfredi; Bernardo Stefanini; Naoshi Nishida et al.
Source: check_circle
Crossref

Reply: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment

Hepatology
2025-03 | Journal article
Contributors: Ciro Celsa; Giuseppe Cabibbo; David J. Pinato
Source: check_circle
Crossref

Data from Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death

2025-02-03 | Preprint
Contributors: Giuseppe Cabibbo; Ciro Celsa; Salvatore Battaglia; Marco Enea; Gabriele Di Maria; Alessandro Grova; Roberta Ciccia; Giulia F. Manfredi; Massimo Iavarone; Arndt Vogel et al.
Source: check_circle
Crossref

Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death

Clinical Cancer Research
2025-02-03 | Journal article
Contributors: Giuseppe Cabibbo; Ciro Celsa; Salvatore Battaglia; Marco Enea; Gabriele Di Maria; Alessandro Grova; Roberta Ciccia; Giulia F. Manfredi; Massimo Iavarone; Arndt Vogel et al.
Source: check_circle
Crossref

Supplementary Figure S1 from Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death

2025-02-03 | Preprint
Contributors: Giuseppe Cabibbo; Ciro Celsa; Salvatore Battaglia; Marco Enea; Gabriele Di Maria; Alessandro Grova; Roberta Ciccia; Giulia F. Manfredi; Massimo Iavarone; Arndt Vogel et al.
Source: check_circle
Crossref

Supplementary Table 1 from Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death

2025-02-03 | Preprint
Contributors: Giuseppe Cabibbo; Ciro Celsa; Salvatore Battaglia; Marco Enea; Gabriele Di Maria; Alessandro Grova; Roberta Ciccia; Giulia F. Manfredi; Massimo Iavarone; Arndt Vogel et al.
Source: check_circle
Crossref

Supplementary Table 2 from Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death

2025-02-03 | Preprint
Contributors: Giuseppe Cabibbo; Ciro Celsa; Salvatore Battaglia; Marco Enea; Gabriele Di Maria; Alessandro Grova; Roberta Ciccia; Giulia F. Manfredi; Massimo Iavarone; Arndt Vogel et al.
Source: check_circle
Crossref

Supplementary Table 3 from Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death

2025-02-03 | Preprint
Contributors: Giuseppe Cabibbo; Ciro Celsa; Salvatore Battaglia; Marco Enea; Gabriele Di Maria; Alessandro Grova; Roberta Ciccia; Giulia F. Manfredi; Massimo Iavarone; Arndt Vogel et al.
Source: check_circle
Crossref

Supplementary Table 4 from Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death

2025-02-03 | Preprint
Contributors: Giuseppe Cabibbo; Ciro Celsa; Salvatore Battaglia; Marco Enea; Gabriele Di Maria; Alessandro Grova; Roberta Ciccia; Giulia F. Manfredi; Massimo Iavarone; Arndt Vogel et al.
Source: check_circle
Crossref

Supplementary Table S5 from Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death

2025-02-03 | Preprint
Contributors: Giuseppe Cabibbo; Ciro Celsa; Salvatore Battaglia; Marco Enea; Gabriele Di Maria; Alessandro Grova; Roberta Ciccia; Giulia F. Manfredi; Massimo Iavarone; Arndt Vogel et al.
Source: check_circle
Crossref

The application of artificial intelligence-based tools in the management of hepatocellular carcinoma: current status and future perspectives

Hepatoma Research
2025-01-09 | Journal article
Contributors: Ciro Celsa; Alessio Quartararo; Marcello Maida; Gaetano Giusino; Valeria Gaudioso; Alba Sparacino; Guido Cusimano; Sofia Rao; Alessandro Grova; Roberta Ciccia et al.
Source: check_circle
Crossref

What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg‐negative anti‐HBc‐positive patients? Meta‐analysis and decision curve analysis

Liver International
2024-11 | Journal article
Contributors: Ciro Celsa; Giacomo E. M. Rizzo; Gabriele Di Maria; Marco Enea; Marco Vaccaro; Gabriele Rancatore; Pietro Graceffa; Giuseppe Falco; Salvatore Petta; Giuseppe Cabibbo et al.
Source: check_circle
Crossref

Data from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Data from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

Clinical Cancer Research
2024-06-03 | Journal article
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Figure S1 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Figure S1 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Figure S10 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Figure S10 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Figure S11 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Figure S11 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Figure S12 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Figure S12 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Figure S13 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Figure S13 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Figure S14 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Figure S14 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Figure S15 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Figure S15 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Figure S2 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Figure S2 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Figure S3 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Figure S3 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Figure S4 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Figure S4 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Figure S5 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Figure S5 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Figure S6 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Figure S6 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Figure S7 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Figure S7 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Figure S8 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Figure S8 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Figure S9 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Figure S9 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Methods S1 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Methods S1 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Methods S2 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Methods S2 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref

Supplementary Methods S3 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

2024-06-03 | Preprint
Contributors: David J. Pinato; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Alexandra Emilia Schlaak; Ciro Celsa; Saskia Killmer; Jesus Miguens Blanco; Caroline Ward; Charalampos-Vlasios Stikas; Mark R. Openshaw et al.
Source: check_circle
Crossref
Items per page:
Page 1 of 3

Peer review (16 reviews for 8 publications/grants)

Review activity for BMC gastroenterology (1)
Review activity for Cancer treatment reviews. (1)
Review activity for Digestive and Liver Disease. (8)
Review activity for Hepatoma research. (1)
Review activity for Internal and emergency medicine. (2)
Review activity for Journal of clinical medicine. (1)
Review activity for PloS one. (1)
Review activity for The European journal of health economics. (1)